Abzena chooses Sartorius

Published: 12-Mar-2018

Sartorius Stedim Biotech has been named the preferred equipment supplier to Abzena CDMO facilities in the US

Abzena plc, the global provider of proprietary technologies and services to biopharmaceutical manufacturers, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the US. The company has selected Sartorius to equip its integrated CDMO facilities in Bristol, Pennsylvania, and San Diego, California.

As part of the agreement, Sartorius Stedim will provide both facilities with end-to-end process solutions in single-use (SU) format.

Reinhard Vogt, Sartorius executive VP, commented: “We are pleased to have been selected by Abzena, a prominent global CDMO with a comprehensive industry portfolio across a wide range of modalities to supply single-use solutions that enable process development, tech transfer and GMP manufacturing. We look forward to working together to best serve the US and international markets.”

Abzena’s Bristol site focuses on development and GMP manufacture of antibody drug conjugates, while the San Diego facility on the development and GMP manufacture of monoclonal antibodies and other recombinant proteins.

The agreement will see Sartorius equip Abzena’s San Diego process development lab with industry technologies such as Ambr250, enabling fast scale up to 500L initially and later to the 2000L scale single-use bioreactor for its centre of excellence in clinical manufacturing.

John Burt, Abzena CEO, said that in addition to having selected Sartorius’ SU technologies for antibody and ADC production, the Abzena facilities will feature Umetrics process analytics software throughout the process. He explained that the technology would make sure that all the data captured throughout its clients’ molecule development is transformed into process knowledge. "We can rapidly develop a robust and reliable process that can be easily scaled up to ensure a smooth technology transfer,” Burt concluded.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like